Letter to the Editor
Split Viewer
Blood Res 2013; 48(3):
Published online September 25, 2013
https://doi.org/10.5045/br.2013.48.3.233
© The Korean Society of Hematology
Relationship between bortezomib-containing regimens and the incidence of tuberculosis in patients with myeloma
1Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
2Department of Internal Medicine, Kyung Hee University Hospital, Seoul, Korea.
Correspondence to : Kihyun Kim. Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine 81, Irwon-ro, Gangnam-gu, Seoul 135-710, Korea. kihyunkimk@gmail.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
TABLES
REFERENCES
- Nucci, M, Anaissie, E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis, 2009;49;1211-1225.
- Ahn, JS, Rew, SY, Yang, DH, et al. Poor prognostic significance of Mycobacterium tuberculosis infection during bortezomib-containing chemotherapy in patients with multiple myeloma. Blood Res, 2013;48;35-39.
PDF
Standard view
Export citation
Share Article
Letter to the Editor
Blood Res 2013; 48(3): 233-234
Published online September 25, 2013 https://doi.org/10.5045/br.2013.48.3.233
Copyright © The Korean Society of Hematology.
Relationship between bortezomib-containing regimens and the incidence of tuberculosis in patients with myeloma
Kihyun Kim1*, Seok Jin Kim1, and Chi Hoon Maeng1,2
1Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
2Department of Internal Medicine, Kyung Hee University Hospital, Seoul, Korea.
Correspondence to: Kihyun Kim. Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine 81, Irwon-ro, Gangnam-gu, Seoul 135-710, Korea. kihyunkimk@gmail.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
-
Table 1 . Bortezomib-containing combination regimens (N=349)..
References
- Nucci, M, Anaissie, E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis, 2009;49;1211-1225.
- Ahn, JS, Rew, SY, Yang, DH, et al. Poor prognostic significance of Mycobacterium tuberculosis infection during bortezomib-containing chemotherapy in patients with multiple myeloma. Blood Res, 2013;48;35-39.
Previous Article
